UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE
CURRICULUM VITAE
FRANCISCO VEGA, MD, PhD

1. Date: January, 2017

I. PERSONAL
2. Current Academic Rank: Professor
3. Primary Department: Pathology (Hematopathology)
4. Secondary Joint Appointment: Clinical Medicine (Professor)
5. Citizenship: United States of America
6. Visa Type: N/A

II. HIGHER EDUCATION:
11. Institutional:
   University Complutense of Madrid, Doctor of Medicine and Surgery, June 1992
   Madrid, Spain
   University of Navarra
   Doctor of Philosophy (Cell Biology), 1997
   Pamplona, Spain

12. Non-Institutional:
   Residency: Department of Anatomic Pathology, Clinical
   University of Navarra, Pamplona, Spain

   Fellowship: Department of Hematopathology, Research
   The University of Texas MD Anderson Cancer Center
   December 1999 – August 2002

   Fellowship: Department of Pathology, Research
   Baylor College of Medicine
   September 2002 – March 2003

   Residency: Department of Anatomic Pathology, Clinical
   Baylor College of Medicine
March 2003 – March 2005

Fellowship: Department of Hematopathology, Clinical
The University of Texas MD Anderson Cancer Center

13. Certification, Licensure:

Florida Medical Board, June 2013 – January 2017
Texas Medical Board, October 2006 –November 2015
American Board of Hematopathology, September 2007
American Board of Anatomic Pathology, August 2005
License in Anatomic Pathology, Spain, December 1997
License in Medicine and Surgery, Spain, July 1992
Educational Commission for Foreign Medical Graduates, August 2002
Indiana Medical Board, 2005 – 2007 (inactive)

III. EXPERIENCE/SERVICE

14. Academic Appointments

University of Miami/Sylvester Comprehensive Cancer Center
Professor, Department of Clinical Medicine
July 2015 – Present

University of Miami/Sylvester Comprehensive Cancer Center
Professor, Hematopathology, Department of Pathology
September 2013 – Present

Member of the Sheila and David Fuente Graduate Program in Cancer Biology
University of Miami
February 2014-Present

The University of Texas MD Anderson Cancer Center
Associate Professor, Tenure, Department of Hematopathology, Pathology/Lab Medicine
September 2011- August 2013

The University of Texas MD Anderson Cancer Center
Assistant Professor, Department of Hematopathology
July 2006 – September 2011

15. Hospital Appointments
Complejo Hospitalario de Orense (Spain)
Faculty, Department of Anatomic Pathology
January 1998 –November 1999

16. **Non-Academic:** None

17. **Military:** None

**IV. PUBLICATIONS**

18. **Books and Monographs published:**


Author of the following chapters for the Book Diagnostic Pathology Series Amirsys:


Syphilitic Lymphadenitis 2:54-55,
Inflammatory Pseudotumor Involving Lymph Node 3:2-7,
Diffuse Large B-cell Lymphoma, NOS, centroblastic 6:52-55,
Diffuse Large B-cell Lymphoma, NOS, Immunoblastic 6:56-61,
T-cell/Histiocyte Rich Large B-cell Lymphoma 6:62-65,
Plasmablastic Lymphoma 7:68-77,
Primary effusion lymphoma (PEL) and solid variant of PEL 7:78-83,
Primary Mediastinal (Thymic) Large B-cell Lymphoma 7:34-43,
Lymphomatoid Granulomatosis 7:86-95,
Intravascular Large B-cell Lymphoma 7:96-101,
B-cell Lymphomas, unclassifiable, with features intermediate between Diffuse Large B cell Lymphoma and Classical Hodgkin Lymphoma 8:8-17,
Anaplastic Large Cell Lymphoma, ALK+ 9:30-35,
Anaplastic Large Cell Lymphoma, ALK-, 9:36-39,
Classical Hodgkin Lymphoma in Spleen, 14:82-85
Hepatosplenic T-cell Lymphoma, 14:86-95.

- Author of additional chapters for the Diagnostic Pathology Series for the following books:


Diagnostic Pathology Spleen. In A. Auerbach editor. Amirsys publishing, 2014

Manuals, Teaching Aids


19. Juried or Refereed Journal Articles or Exhibitions:


38. Vega F. Time to look for CD30 expression in diffuse large B cell lymphomas, along the way to immunotherapy. Leuk Lymphoma 54:2341-2; 2013.


49. Moretti L, Medeiros LJ, Kunkalla K, Williams MD, Singh RR, Vega F. N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas. Mod Pathol 25;231-6, 2012.


plasma cell myeloma have nearly identical immunophenotypic profiles. Mod Pathol 18:806-815, 2005.


20. Other Works, Publications, and Abstracts:

Letters to the Editor


Abstracts in National and International Meetings


55.-Bourbon E, Qu C, Liu Y, Kunkalla K, Liang CS, Leventaki V, Martinez F, Singh R, Agarwal NK, Vega F. Diffuse large B-cell lymphoma cells promote paracrine NF-KB
activation in stromal cells and monocytes that is mediated by the hedgehog receptor smoothened (SMO). Tumor Microenvironment Complexity, AACR, Orlando, FL. 2011


58.-Leventaki L, Kunkalla K, Liu Y, Qu C, Agarwal N, Medeiros LJ, Vega F. Expression of Aldehyde dehydrogenase 1 (ALDH1) by tumor-infiltrating macrophages and dendritic cells in mature B cell lymphomas. Symposia on Cancer Research 2012: Immunology and Inflammation in Cancer. MD Anderson Cancer Center, Houston, 10/2012


60.-Agarwal NK, Qu C, Kunkalla K, Liu Y, Vega F. GLI1 Directly Regulates the Transcription of AKT Genes in Diffuse Large B-Cell Lymphoma. Blood 120A, 2399, 2012


64.-Agarwal NK, Kunkalla K, Hawke DH, Liu Y, Qu C, Vega F. The inhibitor of NF-κB kinase, IKKβ, regulates the stability of GLI1 transcription factor. AACR 2014; San Diego.


69.-Agarwal NK, Kunkalla K, Kin CH, Lossos I, Vega F. The Inhibitor of NF-kB Kinase, IKKβ Regulates the Transcriptional Activity of GLI1 By Blocking Its Proteasomal Degradation ASH 2014; San Francisco

70.-Agarwal NK, Kunkalla K, Kin CH, Vega F The Inhibitor of NF-kB Kinase, IKKβ, Regulates the Stability of the Hedgehog Transcription Factor GLI1. USCAP 2015, Boston

71.-Zhou X; Rosenblatt J; Vega F; Cho-Vega JH. Selection and Rapid Proliferation of an Aggressive Transformed Mycosis Fungoides Clone in a Patient with Classic Mycosis Fungoides and Invasive Ductal Carcinoma Treated with Cytotoxic Chemotherapy. 23rd World congress of Dermatology 2015, Vancouver, Canada


78.-Gajzer DC, Tjendra Y, Kunkalla K, Kim CH, Ikpatt OF, Chapman J, Sanchez S, Yang G, Kwon D, Vega F, Agarwal NK. Clinical and Biological Significance of GLI1 Expression in Diffuse Large B-Cell Lymphoma. USCAP 2016, Seattle


80.-Agarwal NK, Kim CH, Kunkalla K, Tang G, Tjendra Y, Liu Y, Qu C, Vega F. Smoothened (SMO) is an adaptor protein that recruits TRAF6 and phospholipase C gamma 2 (PLCg2) to enhance the activation of NF-kB signaling pathway. ASH 2015, Orlando, FL


21. Other Works Accepted for Publication:

V. PROFESSIONAL

22. Funded Research

Active

1-U01-CA-195568-01 (Lossos/Cerhan) 6/23/15 - 5/31/20
NIH-NCI $155,089
Lymphoma Epidemiology of Outcomes (LEO) cohort study.
Role: Co-Principal Investigator

Completed

S1400141 (Lossos) 8/1/14 - 7/31/16
SCCC $50,000
The Role of LMO2 in Double Strand DNA Repair and Lymphoma Pathogenesis
Role: Co-Investigator
M1501625 (Vega) 6/1/15 - 5/31/16
Women’s Cancer Association $50,000
Effect of Combining SMO and BTK Inhibitors in a Human Diffuse Large B Cell Lymphoma Xenograft Model
Role: Principal Investigator

CTSI FY15Pilot Program Award (Vega) 6/1/2014 - 5/31/2015
Miami CTSI
IKKβ Regulates the Transcriptional Activity of GLI1 in Diffuse Large B-Cell
Lymphoma. $50,000
Role: PI

K08CA14315101 Physician-Scientist, K08 award. Role of Sonic Hedgehog Signaling in Diffuse Large B-Cell Lymphomas. Effort 75% (9 calendar months), NIH/NCI, 9/8/2010−8/31/2014, $511,920
Role: Physician-Scientist

6235-11 (Vega) 10/1/2010−9/30/2014
Hedgehog Signaling a Therapeutic Target for Diffuse Large B-cell Lymphoma, Translational Research Program, Effort 1% (0.12 calendar months), Leukemia and Lymphoma Society, $600,000
Role: PI

Cross-talking between Smoothened and NF-KB Signaling Pathway in Diffuse large B Cell Lymphoma, Effort 6% (0.7 calendar months), MD Anderson Institutional Research Fund Application, 7/2012−6/2014, $50,000
Role: PI

Sonic Hedgehog Signaling Pathway as a Therapeutic Target in Diffuse Large B-cell Lymphoma, Effort 10% (1.2 calendar months), MD Anderson Institutional Research Fund Application, 7/2008−7/2010, $50,000
Role: PI

Identification and Characterization of Tumor Initiating Cells in Chronic Lymphocytic Leukemia, Effort 10% (1.2 calendar months), 03-07-02531, CLL Global Research Foundation, 12/19/2007−12/28/2009, $200,000
Role: PI

Hedgehog Signaling a Therapeutic Target for Diffuse Large B-Cell Lymphoma, Effort 1% (0.12 calendar), Developmental Research Award SPORE Lymphoma, 5/2010−5/2011, $35,000
Role: PI

Role of Hedgehog Signaling in Diffuse Large B-Cell Lymphoma, Wendy Will Case Cancer Foundation, 2009, $35,000
Role: Mentor of Dr. Rajesh Singh (Instructor, Department of Hematopathology at MDACC)

Targeting Sonic Hedgehog Signaling to Overcome Chemoresistance in Diffuse Large B-Cell Lymphoma, Effort 1% (0.12 calendar months), Lauri Strauss Leukemia Foundation, New York, 4/1/2010−3/31/2011, $25,000.
Role: Co-PI and mentor of Dr. Rajesh Singh (Instructor, Department of Hematopathology),

Array-Based Comparative Genomic Hybridization (aCGH) in splenic and nodal marginal
zone lymphomas, MD Anderson Cancer Center Pathology Department Funds, 2005–2006, $10,000
Role: PI and mentor of Vicky Leventaki (fellow, department of hematopathology at MDACC)

**Protocols**

Principal Investigator, Preclinical study sponsored by NIH CTEP in collaboration with Genentech to assess the utility of Hedgehog inhibitor GDC-0449 in diffuse large B-cell lymphomas. 2009, Pre-clinical trial, NIH/NCI, 2009.

Principal Investigator, Preclinical study with Genentech to assess the utility of Hedgehog inhibitor G025698 in diffuse large B-cell lymphoma, Pre-clinical trial, Genentech, 2009

Collaborator, Immunophenotypic and Molecular Characterization of HIV -Related Plasmablastic Lymphomas and Plasma Cell Myelomas/Plasmacytomas, LAB04-0457.

Collaborator, single-arm, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with Follicular Lymphoma who are refractory to rituximab as monotherapy or in combination with chemotherapy (protocol Hx-CD20-405).


Collaborator, Phase 2 Study of the HSP90 Inhibitor AUY922 in Patients with Relapsed and Refractory Lymphoma, 2011-0467, 2011
Collaborator, Phase 2 Study of Brentuximab Vedotin (SGN -35) in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma (NHL), 2011-0442, 2011

Collaborator, Phase III, multicenter, open-label, randomized trial comparing the efficacy of GA101 in combination with CHOP versus rituximab and CHOP in previously untreated patients with CD20-positive DLBCL. 2012-1155
Collaborator, SPI-ZV-11-301, phase III, open label, multicenter, randomized study of sequential zevalin (ibritumomab tiuxetan) versus observation in patients at least 60 years of age with newly Diagnosed diffuse large B-cell lymphoma in PET-negative complete remission after R-CHOP or R-CHOP-like therapy 2012-0504

Collaborator, A randomize, double bind, placebo-controlled, multicenter phase III study of RAD001 adjuvant therapy in poor risk patients with DLBCL of RAD001 versus matching placebo after patients have achieved complete response with first line rituximab chemotherapy 2009-0973

Collaborator, Phase II study of BKM120 I patients with relapsed and refractory diffuse large B cell lymphoma, mantle cell lymphoma and follicular lymphoma.

23. Editorial Responsibilities

Editor/Service on Editorial Board(s)

Chief Editor, Internet Journal of Pathology, 2006–2008

Member of Editorial Review Board

Member Editorial Board of Human Pathology: Case Reports since 2016
Scientific Advisor of the Lymphoma Research Foundation (LFR) since 2016
Member Patient Publications Medical Review Committee of the Lymphoma Research Foundation (LRF) 2015
Editor Board Member, Annals of Diagnostic Pathology, 2012-present
Editor Board Member, International Journal of Clinical and Experimental Pathology, 2010–present
Associate Editor, American Journal of Blood Research, 2011-present

Journal Reviewer (since 2006 until present)

Grant Reviewer
Grant Reviewer for Bloodwise (previously Leukemia Lymphoma Research) Clinical Research Training Fellowship. London, UK, 2016
Reviewer for the Mentoring and Career Development K12 award. CTSI University of Miami, 2015.

Reviewer for the Paracelsus Medical University (PMU) Research Fund (FFF) of the PMU Salzburg, Germany, 2014

Reviewer for NCI Special Emphasis Panel, Training and Career Development, 2013

Reviewer for the MDACC Institutional Grant Review Committee, MD Anderson, Member, 2009–2013

Reviewer for the Career Development Awards, NIH Scientific Review Group, 2012-2013

Grant reviewer for the Le Comité d’évaluation du programme Emergence 2012 from the French National Research Agency (ANR) (France), 2012

Reviewer for MDACC Sister Institution Network Foundation, Grant Reviewer, 2012

Grant reviewer for the chronic lymphocytic leukemia (CLL) Global Research Foundation, 2010

Grant reviewer for the Medical Research Council, London (UK), 2010

**Other Review Activities**

Reviewer of oral and poster abstracts, section of Non-Hodgkin Lymphoma: Biology, excluding Therapy. American Society of Hematology (ASH), 2015


Judge for the poster presentation of the Experimental Therapeutics Academic Program’s student retreat, University of Texas, MD Anderson Cancer Center, 2012

**24. Professional and Honorary Organizations:**

Member, Spanish Society of Pathologists, Spain 1994–Present

Member, American & Canadian Academy of Pathology 1996–Present

Member, College of American Pathologists 2003–Present

Member, American Society of Hematology 2006–Present

Member, Society of Hematopathology/European Association for Haematopathology 2006-Present

Member, American Association for Cancer Research 2008–Present

Member, International Society of Stem Cell Research 2007–2010

Member, Texas Society of Pathologists, Houston, TX 2003–2013

**25. Honors and Awards:**

Scholarship from the Government of Navarra, Pamplona, Spain, 1996

"Manual Cabaleiro Goas" Award, Official School of Medical Doctors of Orense, Best Scientific Work 1998
Award for Best Platform Presentation, XX Meeting of the Galician Society of Gastroenterology, 1999

Postgraduate Grant from the Fundacion Pedro Barrie de la Maza La Coruna, Spain, 1999-2001

The Janice Davis Singletary Award for Clinical Fellowship in Lymphoma, MD Anderson Cancer Center, 2006

Mentor of Keith Newton, undergraduate student, awarded with the Annual Research Student Award of the Association of Genetic Technologists, 2008

Mentor of Raj Davuluri, pre-medical student, 1st Place of DeBakey Premedical School Research Award, Baylor College of Medicine, Houston, Texas, 2009

Mentor of Vicky Leventaki, fellow hematopathology, fellow research grant (funds from the Department of pathology at MDACC) “Immunophenotypic characterization of aldehyde dehydrogenase 1 (ALDH1) positive stromal dendritic cells in malignant lymphoma” 2012.

Mentor of Changju Qu, postdoctoral fellow in my laboratory, awarded with the Abstract achievement award, American Society of Hematology (ASH) meeting, San Diego, 2011.

Mentor of Changju Qu, postdoctoral fellow in my laboratory awarded with the Abstract achievement award, American Society of Hematology (ASH) meeting, Atlanta, 2012.

26. Other Professional Activities:

Organization of Conferences/Courses

2011 American Society of Clinical Pathology/WASPaLM XXVI World Congress, Co-director of the educational hematopathology course, Las Vegas, NV, Co-director, 10/2011

Course/session moderator
57th Annual Meeting of the American Society of Hematology (ASH), Moderator of the Oral Session entitled "Non-Hodgkin's Lymphoma-Biology, excluding therapy: Clinical implications of genomic studies of B cell lymphoma, Moderator, 12/2015

Moderator of the Hematopathology session in the United States and Canadian Academy of Pathology (USCAP). Baltimore, 2013


Invited Presentations Courses and from Other Institutions
Role of SMO in the biology of diffuse large B cell lymphoma. Fox Chase Cancer Center, Philadelphia 11/2016

Role of SMO in the biology of diffuse large B cell lymphoma. 18th meeting of the European Association for Haematopathology, Basel, Switzerland, 9/2016


Cross Talk between Hedgehog and NF-kB Pathways: A Novel Finding in the Pathobiology of Diffuse Large B Cell Lymphoma with Potential Therapeutic Implications. LVII National Congress of the Spanish Society of Hematology (SEHH) and XXXI National Congress of the Spanish Society of Thrombosis and Hemostasis. Valencia (Spain). 10/2015


Role of Hedgehog signaling in the pathobiology of diffuse large B-cell lymphoma. Department of Pathology, Memorial Sloan Kettering, New York. 8/2015.

Role of Hedgehog signaling in the pathobiology of diffuse large B-cell lymphoma. Department of Pathology, Ann Arbor, University of Michigan. 5/2015.


Understanding primary cutaneous T-cell lymphomas (non-mycosis fungoides). Santiago de Chile, Chile 10/2014.
Pathobiology of chronic lymphocytic leukemia/small lymphocytic lymphoma. Santiago de Chile, Chile 10/2014.

Diffuse large B cell lymphomas: Advances in Diagnosis. 38th annual Review and Practical Advances in Pathology. Miami, FL. 2/2014

Role of Hedgehog signaling in the biology of diffuse large B-cell lymphoma. Department of Pathology, University of Miami. 3/2013.

Role of Hedgehog signaling in the biology of diffuse large B-cell lymphoma. Department of Pathology, City of Hope, Duarte, California 2/2013.

Role of Hedgehog signaling in the biology of diffuse large B-cell lymphoma. Department of Pathology, University of North Carolina Chapel Hill, 8/2012.


Understanding Cutaneous Lymphomas. Pathology Ground Rounds. Nebraska University, Omaha 5/2012.

Hedgehog signaling pathway: a potential therapeutic target for diffuse large B-cell lymphoma. Ground Rounds, Department of Pathology, University of Miami. 2/2012.


Hedgehog signaling pathway: a potential therapeutic target for malignant lymphomas, Ground Rounds, Seoul National University Cancer Center, Seoul, South Korea, 4/2011.


Hedgehog signaling pathway: a potential therapeutic target for malignant lymphomas, Asan Medical Center, Seoul, South Korea, 4/2011.

Lymphoma and Hematopoietic neoplasms involving skin, Surgical Pathology Update, Daegu, South Korea, 4/2011.
Hedgehog signaling in lymphomas, Pathology Ground Rounds, Cleveland Clinic, Cleveland, OH, 11/2010.


Diffuse large B-cell lymphoma in the 2008 WHO classification, Update course of Surgical Pathology, Sao Paolo, Brazil, 4/2009.

T-cell lymphomas in the 2008 WHO classification, Update course of Surgical Pathology, Sao Paolo, Brazil, 4/2009.

Aggressive B-cell lymphomas, Update Course of Surgical Pathology, Viña del Mar, Chile, 4/2008.

Anaplastic Large Cell Lymphoma, Update Course of Surgical Pathology, Viña del Mar, Chile, 4/2008.

Aggressive B-cell lymphomas, IV National Congress of Hematology and Oncology, Antigua, Guatemala, 8/2008.

Anaplastic large cell lymphomas, IV National Congress of Hematology and Oncology, Antigua, Guatemala, 8/2008.

Short Course: Bone Marrow Pathology, 3rd Intercontinental Congress of Pathology, Barcelona, Spain, 5/2008.

Anaplastic large cell lymphomas (ALK-positive and ALK negative), XXII Meeting of the Spanish Society of Pathology, Palma de Mallorca, Spain, 6/2006.

T- and NK-cell lymphomas, Workshop, Society of Hematopathloghy/European Association of Hematopathology, Houston, TX, 10/2005.

Aplicaciones de la patologia molecular en el estudio del cancer, Pasado, Presente y Futuro, Jornadas de Asma Y EPOC, Cristal-Pinor Hospital, Orense, Spain, 5/2004.

Celulas fibroblasticas del ganglio linfatico. Reunion Nacional del Club de Linfomas,
Hospital Juan Canalejo, La Coruna, Spain, 5/2004.

GeneScan and Real Time PCR, I Course of Molecular Pathology, Universidad de Navarra, Pamplona, Spain, 6/1/2002.

Probematica del diagnostico y clasificacion anatomopatologico de la Fibrosis Pulmonar Idiopatica (FPI). Mesa Redonda en Neumopatias Intersticiales y de Origen Ocupacional, Hospital do Meixoeiro, Vigo, Spain, 5/1999.

Utilidad de la inmunohistoquimica y biologia molecular en tejido linfoide necrotico, IX Course of Surgical Pathology, San Sebastian Hospital, San Sebastian, Spain, 10/1997.

**Other Presentations at State and Local Conferences**

Molecular Hematopathology I Medical Oncology Core Curriculum, University of Miami/Sylvester Cancer Center, Miami, 9, 2015

Molecular Hematopathology II Medical Oncology Core Curriculum, University of Miami/Sylvester Cancer Center, Miami, 9, 2015


The inhibitor of NF-kB kinase, IKKb, regulates the transcriptional activity of GLI1 by blocking its proteosomal degradation. Epigenetics and Cancer Colloquium Sylvester Comprehensive Cancer Center, Miami, FL, 8/2014


IKKb stabilizes GLI1 and contributes to the activation of hedgehog signaling pathway. Retreat Meeting Sylvester Comprehensive Cancer Center, University of Miami, FL, 3/2014

Role of Hedgehog Signaling in Diffuse Large B-cell Lymphoma. Research Seminar, Hematopoietic malignancy group. Sylvester Cancer Center/University of Miami, FL, 2/2014

Role of Hedgehog Signaling in Diffuse Large B-cell Lymphoma. Research Seminar, MOET program meeting. University of Miami, FL, 1/2014

Role of SMO and GLI1 in diffuse large B cell lymphoma. Leukemia Research Seminar, University of Texas MD Anderson Cancer Center, Houston, TX, 6/2013
Diffuse large B-cell lymphoma, updates in new therapeutic approaches, Pathology Grand Rounds, University of Texas Medical Branch, Galveston, TX, 2012

Update in hedgehog signaling in diffuse large B-cell lymphoma, Leukemia Research Seminar, University of Texas MD Anderson Cancer Center, Houston, TX, 4/2012

Hedgehog signaling pathway: a potential therapeutic target for malignant lymphomas, Experimental Therapeutics Research Seminar, University of Texas MD Anderson Cancer Center, Houston, TX, 9/2012

Hedgehog signaling pathway: a potential therapeutic target for malignant lymphomas, Cytogenetic Research Seminar, University of Texas MD Anderson Cancer Center, Houston, TX, 4/2011

Hedgehog signaling pathway: A new therapeutic approach for lymphomas, Leukemia Research Seminar, University of Texas, 9/2010

Role of sonic hedgehog signaling in lymphomas, Cytogenetic Research Seminar, University of Texas MD Anderson Cancer Center, Houston, TX, 3/19/2009

Role of sonic hedgehog signaling in lymphomas and leukemias, Leukemia Research Seminar, University of Texas MD Anderson Cancer Center, Houston, TX, 3/25/2009
Sonic hedgehog signaling is activated by NPM/ALK in ALK-positive anaplastic large cell lymphomas, MD Anderson Cancer Center, Houston, TX, 9/2008

Cancer Stem Cells, Pathology Grand Rounds, MD Anderson Cancer Center, Houston, TX, 3/2008

A molecular approach to monitoring disease progression in mycosis fungoides, The University of Texas MD Anderson Cancer Center, Houston, TX, 4/2001

A novel 4-color PCR assay to assess T-cell receptor gamma gene rearrangements in lymphoproliferative lesions, The University of Texas MD Anderson Cancer Center, Houston, TX, 4/2001

VI. TEACHING

27. Teaching Awards Received:

Best teacher department of pathology, University Clinic of Navarra, years 1995-1997

28. Teaching Specialization:

Training Programs

Speaker, Principles in Neoplastic Hematology Lecture Series MD Anderson Cancer Center 2006–2008
Speaker, Cytogenetics Seminars, MD Anderson Cancer Center, 2006–2010
Speaker, Lymphoma Seminars, MD Anderson Cancer Center, 2006
Speaker, Current Topics in Human and Molecular Genetics Seminars, MD Anderson Cancer Center 2013.

29. Thesis and Dissertation Advising/Post-doctoral Student Supervision:

Since 2006- Direct supervision of undergraduate, graduate and medical students; postdoctoral fellows, research scientist, instructors and technicians in my research laboratory.

Undergraduate students: 10 (Keith Newton, Yogesh Davuluri, Christine Cain, Elsa Ramirez, Noelia Baez Rivera, Cynthia Liang, Kunal S Dave, Estelle Bourbon, Gloria Yang, Alexa Constantakos)
Medical Student: 1 (Yogesh Davuluri)
Graduate students: 2 (Beatriz Sanchez-Espiridon, Changju Qu)
Postdoctoral fellows: 7 (Rajesh Singh, Changju Qu, Chae H Kim, Christine Militto, Ji Eun Kim, Kim Chae Hwa, Youley Tjendra)
Research Scientist: 1 (Nitin Agarwal)
Instructor: 1 (Rajesh Singh)

Supervisor of clinical hematopathology fellows, MD Anderson Cancer Center 7/2006–8-2013 (4 to 6 fellows per year since 2006)

Supervisor of hematopathology fellows and Pathology residents, University of Miami, 9/2013-current (2 fellows per year; and 2 rotating pathology residents per month)

Supervisor of hematopathology visitors, University of Miami: 5 international visitors since 2013: Sandra Sanchez (Colombia), Jose Luis Solorzano (Spain), Hernan Quiceno (Spain), Ivan Gonzalez (Dominican Republic), Kumar Ganesh (India)

Teaching Outside of Current Institution

Previous Formal Teaching


VII. SERVICE

30. University Committee and Administrative Responsibilities:

Member of the Medical School Faculty Council. University of Miami, 2016-present

Member of the IRB committee of the University of Miami/Sylvester Comprehensive Cancer Center, 2015-present

Member of the Quality Assessment committee of the Department of Pathology, University of Miami, 2015-present

Member of the Research Committee of the Department of Pathology, University of Miami, 2015-present

Member of the Cancer Biology Graduate Program, University of Miami, 2014-present

Director of Division of Hematopathology
University of Miami/Sylvester Comprehensive Cancer Center
September 2013 – Present

Member of the Hematologic Malignancy Program, University of Miami/Sylvester Cancer Center, 2013-present

Member of the Leukemia/lymphoma faculty recruit committee, University of Miami/Sylvester Cancer Center, 2013-2014

Faculty, Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, until 8/2013

Member of the Human and Molecular Genetics Program, 2012-8/2013 The University of Texas MD Anderson Cancer Center

Member of the Experimental Therapeutics Program, 2012-8/2013 The University of Texas MD Anderson Cancer Center

Lymphoma Section Head, Department of Hematopathology, Path/Lab Medicine
The University of Texas MD Anderson Cancer Center
January 2011 – August 2013

MD Anderson Cancer Center, Institutional Grant Review Committee (IRG), Member, 2009–2013.

MD Anderson Cancer Center, Institutional Large Cell Lymphoma Group, Member, 2011-2013.

MD Anderson Cancer Center, Institutional T-cell lymphoma Group, Member, 2011-2013.
MD Anderson Cancer Center, Institutional Hodgkin lymphoma Group, Member, 2011-2013.

MD Anderson Cancer Center, Institutional Credentialing Committee - Alternate Member, 8/2011-2013.

Member of advisory committee of graduate students, University of Texas, 2012-2013

Strike Force, Pathology Department, MD Anderson Cancer Center, Member, 2007–2009.

Medical and Surgical Academy of Orense (Spain), Member, 1/1998–11/1999.
Research Commission of Complejo Hospitalario de Orense (Spain), Member, 1/1998–11/1999.

Commission of Tissue and Mortality of Complejo Hospitalario de Orense (Spain), Member, 1/1998–11/1999.